National Bank of Canada
IPSC icon

National Bank of Canada’s Century Therapeutics IPSC Stock Holding History

National Bank of Canada’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,500
Closed -$21K – 2787
2022
Q2 		$21K Buy
+2,500
New +$24.5K ﹤0.01% 2064

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

National Bank of Canada's IPSC Position: Q3 2022 in Review

National Bank of Canada sold out of Century Therapeutics (IPSC) in Q3 2022, closing a stake of 2,500 shares — an estimated $21K sold.

National Bank of Canada first reported a position in IPSC in Q2 2022 and held it in 1 quarter. The position peaked at $21K in Q2 2022. 54 funds tracked by Wall St. Rank hold IPSC as of Q3 2022.

  • National Bank of Canada reported no remaining Century Therapeutics position as of Q3 2022 after selling out during the quarter.
  • National Bank of Canada sold 2,500 Century Therapeutics shares in Q3 2022, an estimated $21K.
  • National Bank of Canada first reported a position in Century Therapeutics in Q2 2022 and held it in 1 quarter.
  • National Bank of Canada's Century Therapeutics position peaked at $21K in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2022.

Based on National Bank of Canada's 13F filing for Q3 2022, filed 13 Oct 2022.